Skip to main content

Table 3 Indirect comparisons of the effects of IVT-AFL 2q8 versus IVR 0.5 mg PRN on 12-month visual outcomes using (A) MTC and (B) Bucher analyses

From: Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)

(A)

MTC

Studies (n)

FE: effect size [95% CrI]

RE: effect size [95% CrI]

BCVA mean change from baseline

10 studies (n = 3060)*

MD = 4.67 [2.45–6.87]

MD = 4.67 [1.85–7.52]

Gain ≥ 10 ETDRS letters

6 studies (n = 2810)**

RR = 1.32 [0.98–1.78]

RR = 1.19 [0.90–1.57]

OR = 1.64 [0.97–2.78]

OR = 1.59 [0.75–3.35]

Loss ≥ 10 ETDRS letters

6 studies (n = 2810)**

RR = 0.27 [0.07–0.90]

RR = 0.28 [0.06–1.29]

OR = 0.27 [0.07–0.90]

OR = 0.26 [0.05–1.31]

Gain ≥ 15 ETDRS letters

6 studies (n = 2810)**

RR = 1.78 [0.96–3.29]

RR = 1.42 [0.93–2.24]

OR = 1.90 [0.95–3.75]

OR = 1.87 [0.87–4.16]

Loss ≥ 15 ETDRS letters

6 studies (n = 2810)**

RR = 0.13 [0.004–1.35]

RR = 0.14 [0.007–1.52]

OR = 0.13 [0.004–1.35]

OR = 0.14 [0.006–1.53]

(B)

Bucher

Studies (n)

FE: effect size [95% CI]

RE: effect size [95% CI]

BCVA mean change from baseline

4 studies (n = 1611)***

MD = 4.82 [2.52–7.11]

MD = 4.82 [2.52–7.11]

Gain ≥ 10 ETDRS letters

4 studies (n = 1611)***

RR = 0.993 [0.65–1.52]

RR = 1.00 [0.60–1.66]

OR = 1.32 [0.74–2.35]

OR = 1.32 [0.65–2.68]

Loss ≥ 10 ETDRS letters

4 studies (n = 1611)***

RR = 0.31 [0.09–1.04]

RR = 0.31 [0.09–1.09]

OR = 0.28 [0.08–0.99]

OR = 0.27 [0.08–0.94]

Gain ≥ 15 ETDRS letters

4 studies (n = 1611)***

RR = 1.49 [0.78–2.85]

RR = 1.49 [0.78–2.85]

OR = 1.74 [0.83–3.65]

OR = 1.74 [0.83–3.65]

Loss ≥ 15 ETDRS letters

4 studies (n = 1611)***

RR = 0.24 [0.03–1.90]

RR = 0.26 [0.03–2.11]

OR = 0.23 [0.03–1.86]

OR = 0.23 [0.03–1.86]

  1. *VIVID-DME, VISTA-DME, IBETA, RESTORE, REVEAL, RELATION, DRCR.net Protocol I, DRCR.net Protocol J, LUCIDATE, and Maia et al. [13,15,16,29-35].
  2. **VIVID-DME, VISTA-DME, RESTORE, REVEAL, DRCR.net Protocol I, and DRCR.net Protocol J [13,15,16,32,33].
  3. ***VIVID-DME, VISTA-DME, RESTORE, and REVEAL [13,15,16].
  4. BCVA, best-corrected visual acuity; CI, confidence interval; CrI, credible interval; ETDRS, Early Treatment Diabetic Retinopathy Study; FE, fixed effects; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; MD, mean difference; MTC, mixed treatment comparison; OR, odds ratio; PRN, as needed; RE, random effects; RR, relative risk/risk ratio.